Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

Daniele Santini, Matteo Santoni, Alessandro Conti, Giuseppe Procopio, Elena Verzoni, Luca Galli, Giuseppe di Lorenzo, Ugo De Giorgi, Delia De Lisi, Maurizio Nicodemo, Marco Maruzzo, Francesco Massari, Sebastiano Buti, Emanuela Altobelli, Elisa Biasco, Riccardo Ricotta, Camillo Porta, Bruno Vincenzi, Rocco Papalia, Paolo MarchettiLuciano Burattini, Rossana Berardi, Giovanni Muto, Rodolfo Montironi, Stefano Cascinu, Giuseppe Tonini

Research output: Contribution to journalArticle

Abstract

PURPOSE: We retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma. RESULTS: 37% patients achieve CR with TKI alone, while 63% with additional loco-regional treatments. 49% patients recurred after CR, with a median Disease free survival of 28.2 months. Patients treated with multimodal approaches present lower rate of recurrence (40% vs 61%) and longer Disease free survival compared to patient treated with TKI alone (16.5 vs 41.9 months, p=0.039).Furthermore the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and bone metastasis (50%). Patients who continued TKI therapy after complete response had a longer disease free survival than patients who stopped therapy, although the difference was not significant (42.1 vs 25.1 months, p=0.254). 2y-cDFS was better in patients treated with multimodal treatment and who continued TKIs than the other patient arms.NS: The prognostic value of CR depends on the site where was obtained and how was obtained (with or without locoregional treatment). Cessation of TKI should be carefully considered in complete responder patients.

Original languageEnglish
Pages (from-to)33381-33390
Number of pages10
JournalOncotarget
Volume7
Issue number22
DOIs
Publication statusPublished - May 31 2016

Keywords

  • Complete responder patients
  • Conditional survival
  • Renal cell carcinoma
  • Risk of recurrence
  • Tirosin kinase inhibitor

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Santini, D., Santoni, M., Conti, A., Procopio, G., Verzoni, E., Galli, L., di Lorenzo, G., De Giorgi, U., De Lisi, D., Nicodemo, M., Maruzzo, M., Massari, F., Buti, S., Altobelli, E., Biasco, E., Ricotta, R., Porta, C., Vincenzi, B., Papalia, R., ... Tonini, G. (2016). Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget, 7(22), 33381-33390. https://doi.org/10.18632/oncotarget.8302